NewAmsterdam Pharma doses first patient in Phase 2b SPINOZA trial of obicetrapib in preclinical Alzheimer’s disease

• NewAmsterdam Pharma dosed the first participant in SPINOZA, a Phase 2b trial of obicetrapib in preclinical Alzheimer’s disease.
• Results have not been presented; the study will track whether treatment shifts Alzheimer’s-related blood biomarkers over 52 weeks.
• The trial targets adults with early biomarker evidence of disease but no noticeable symptoms, with enrollment stratified by ApoE genotype.
• About 400 participants will receive obicetrapib 10 mg or placebo, with an optional 26-week extension on active drug.
• The program builds on signals from a biomarker analysis in the Phase 3 BROADWAY study, which guided SPINOZA’s design.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290800PRIMZONEFULLFEED9835515) on September 29, 2026, and is solely responsible for the information contained therein.